Saturday, February 18, 2017 7:17:08 PM
So here is another question, and for the record, I am not into conspiracy theory.
Firstly, have any other products from this PFE facility been delayed for facility compliance concerns? This of course assumes that Glatopa is otherwise ready for approval.
And secondly, given that PFE is Synthon's exclusive partner for commercialization of Synthon's glatiramer acetate in the US, any reason to believe that PFE is slow playing any needed correction action?
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM